<DOC>
	<DOCNO>NCT01516086</DOCNO>
	<brief_summary>This multi-center , randomize , placebo control parallel-group study Replicate Efficacy Nebulized Fluticasone Propionate ( FP ) Adult Subjects Partly Controlled Uncontrolled Asthma . Individual participation approximately 16 week , include 12 week double-blind treatment .</brief_summary>
	<brief_title>A 12-Week Study Adult Subjects With Asthma</brief_title>
	<detailed_description>The primary outcome measure FEV1 ( Forced Expiry Volume 1 second ) secondary outcome measure Peak Expiratory Flow Rate ( PEFR ) , Asthma Control Questionnaire ( ACQ ) , Nighttime awaken rescue medication usage .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>1 . A signed date write informed consent form prior conduct study procedures 2 . Males females ≥ 18 ≤ 60 year old . 3 . Nonsmoker least 1 year prior Visit 1 , smoke history 10 packyears ( e.g. , 1 pack [ 20 cigarette ] per day 10 year ) . 6.Ability understand comply protocol requirement ( include completion daily PEFR , PFT ACQ ) , instruction protocolstated restriction . 7.Women childbearing potential ( WOCBP ) must negative pregnancy test screen visit . WOCBP include : female experience menarche postmenopausal ( define amenorrhea least 12 consecutive month ) , undergone surgical sterilization ( hysterectomy , bilateral oophorectomy , bilateral tubal ligation ) . Women use acceptable contraceptive medication device prevent pregnancy practice abstinence partner sterile ( e.g. , vasectomy ) consider WOCBP . WOCBP must agree avoid become pregnant duration study use adequate contraception study entry throughout trial . Examples adequate contraception include follow : Norplant Medroxyprogesterone acetate injection Oral contraception Doublebarrier method ( e.g. , condom spermicide ) Abstinence , one WOCBP advise notify Investigator change pregnancy status change contraceptive use . 8.Agreement subject abide study protocol restriction . 1 . Past present disease , exclude asthma , judge investigator , may place subject increase risk complication , interfere study participation , confound study objectives These disease include , limited cardiovascular disease , malignancy , gastrointestinal disease , hepatic disease , diabetes type I uncontrolled diabetes , type II , renal disease , haematological disease , neurological disease , endocrine disease pulmonary disease ( include , confine chronic bronchitis , emphysema , bronchiectasis , COPD , eosinophilic bronchitis pulmonary fibrosis ) . 2 . An upper low respiratory tract infection within 4 week Visit 1 prior Visit 2 3 . A history hypersensitivity study drug component , include albuterol rescue medication . 4 . History illegal drug alcohol abuse within past 5 year . 5 . Pregnant lactating woman . 6 . Use &gt; 8 inhalation per day SABA two consecutive day screen randomization ( Visits 1 2 ) . 7 . Use investigational drug device within 30 day prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Controlled</keyword>
	<keyword>uncontrolled</keyword>
</DOC>